Jasper Therapeutics, Inc. (JSPRW)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 21,196 | |||
| General and administrative | 5,880 | |||
| Total operating expenses | 27,076 | |||
| Loss from operations | -27,076 | |||
| Net loss and comprehensive loss | -26,700 | |||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -1.74 | |||
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -1.74 | |||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) | 15,333,962 | |||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) | 15,333,962 | |||